MYmAb Biologics is a trusted tissue microarray company (https://www.mymab.com.my/) providing high-quality human tissue microarrays (TMAs) for both clinical and MYmAb Biologics is a trusted tissue microarray company (https://www.mymab.com.my/) providing high-quality human tissue microarrays (TMAs) for both clinical and

Dr Chua Jia Xin of MYmAb Biologics Wins National Young Scientist Award 2025, Elevating Malaysia’s Biotech Innovation

2025/12/24 03:50
2 min read

MYmAb Biologics is a trusted tissue microarray company (https://www.mymab.com.my/) providing high-quality human tissue microarrays (TMAs) for both clinical and research applications. With a strong commitment to ethical sourcing, rigorous quality standards, and reliable global distribution, MYmAb Biologics supports researchers worldwide in advancing translational research and oncology studies using clinically relevant human tissue samples.

Dr Chua Jia Xin, founder of MYmAb Biologics, has been recognised as the National Young Scientist Award 2025 recipient in the Medical category, highlighting Malaysia’s growing strength in biotechnology talent. Dr Chua has built a reputation for pioneering therapeutic monoclonal antibody development, translating research into therapies that directly target and eliminate cancer cells. One of her UK-developed antibodies has already been licensed for clinical exploration, showcasing the global relevance and impact of her work.

Her mission is to make advanced antibody-based therapies more accessible and affordable for Malaysian patients, reducing reliance on costly imported biologics while elevating the country’s presence in the international biotherapeutics sector. Under her leadership, MYmAb Biologics has also become a trusted provider of tissue microarrays, empowering local and regional scientists with high-quality research tools for oncology and biomarker studies.

Dr Chua’s award reflects her scientific excellence and dedication to real-world impact, ensuring that discoveries lead to practical clinical applications and patient benefit. Her achievement joins those of this year’s other distinguished award recipients, collectively representing a new generation of Malaysian scientists shaping the future of science, technology, and innovation.

To learn more about MYmAb Biologics and its tissue microarray solutions, visit the MYmAb Biologics website.

This news article is provided and written by Pillars Media (https://pillarsmedia.my/).

Comments
Market Opportunity
Mixin Logo
Mixin Price(XIN)
$42.17
$42.17$42.17
-4.52%
USD
Mixin (XIN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Which Altcoins Stand to Gain from the SEC’s New ETF Listing Standards?

Which Altcoins Stand to Gain from the SEC’s New ETF Listing Standards?

On Wednesday, the US SEC (Securities and Exchange Commission) took a landmark step in crypto regulation, approving generic listing standards for spot crypto ETFs (exchange-traded funds). This new framework eliminates the case-by-case 19b-4 approval process, streamlining the path for multiple digital asset ETFs to enter the market in the coming weeks. Grayscale’s Multi-Crypto Milestone Grayscale secured a first-mover advantage as its Digital Large Cap Fund (GDLC) received approval under the new listing standards. Products that will be traded under the ticker GDLC include Bitcoin, Ethereum, XRP, Solana, and Cardano. “Grayscale Digital Large Cap Fund $GDLC was just approved for trading along with the Generic Listing Standards. The Grayscale team is working expeditiously to bring the FIRST multi-crypto asset ETP to market with Bitcoin, Ethereum, XRP, Solana, and Cardano,” wrote Grayscale CEO Peter Mintzberg. The approval marks the US’s first diversified, multi-crypto ETP, signaling a shift toward broader portfolio products rather than single-asset ETFs. Bloomberg’s Eric Balchunas explained that around 12–15 cryptocurrencies now qualify for spot ETF consideration. However, this is contingent on the altcoins having established futures trading on Coinbase Derivatives for at least six months. This includes well-known altcoins like Dogecoin (DOGE), Litecoin (LTC), and Chainlink (LINK), alongside the majors already included in Grayscale’s GDLC. Altcoins in the Spotlight Amid New Era of ETF Eligibility Several assets have already met the key condition, regulated futures trading on Coinbase. For example, Solana futures launched in February 2024, making the token eligible as of August 19. “The SEC approved generic ETF listing standards. Assets with a regulated futures contract trading for 6 months qualify for a spot ETF. Solana met this criterion on Aug 19, 6 months after SOL futures launched on Coinbase Derivatives,” SolanaFloor indicated. Crypto investors and communities also identified which tokens stand to gain. Chainlink community liaison Zach Rynes highlighted that LINK could soon see its own ETF. He noted that both Bitwise and Grayscale have already filed applications. Meanwhile, the Litecoin Foundation indicated that the new standards provide the regulatory framework for LTC to be listed on US exchanges. Hedera is also in the spotlight, with digital asset investor Mark anticipating an HBAR ETF. Market observers see the decision as a potential turning point for broader adoption, bringing the much-needed clarity and accessibility for investors. At the same time, it boosts confidence in the market’s maturity. The general sentiment is that with the SEC’s approval, the next phase of crypto ETFs is no longer a question of ‘if,’ but ‘when.’ The shift to generic listing standards could expand the US-listed digital asset ETFs roster beyond Bitcoin and Ethereum. Such a move would usher in new investment vehicles covering a dozen or more altcoins. This represents the clearest path yet toward mainstream, regulated access to diversified crypto exposure. More importantly, it comes without the friction of direct custody. “We’re gonna be off to the races in a matter of weeks,” ETF analyst James Seyffart quipped.
Share
Coinstats2025/09/18 12:57
Zhongchi Chefu acquired $1.87 billion worth of digital assets from a crypto giant for $1.1 billion.

Zhongchi Chefu acquired $1.87 billion worth of digital assets from a crypto giant for $1.1 billion.

PANews reported on February 10th that Autozi Internet Technology (Global) Ltd. (AZI), a US-listed Chinese company, has successfully acquired approximately $1.87
Share
PANews2026/02/10 20:36
XRP news: Ripple expands RLUSD stablecoin use in UAE via Zand Bank

XRP news: Ripple expands RLUSD stablecoin use in UAE via Zand Bank

Ripple has expanded the reach of its RLUSD stablecoin in the Middle East through a new strategic partnership with UAE-based digital bank Zand, a move that could
Share
Crypto.news2026/02/10 20:08